Bano, Arjola; Laimer, Markus; Wehrli, Faina; Künzler, Juri; Rivero, Tania; Fraser, Alan G; Stettler, Christoph; Hovorka, Roman; Bally, Lia (2023). Clinical evidence for high-risk medical devices used to manage diabetes: protocol for a systematic review and meta-analysis. BMJ open, 13(4), e070672. BMJ Publishing Group 10.1136/bmjopen-2022-070672
|
Text (Article incl. supplemental materials (PRISMA-P, search strategies))
e070672.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (631kB) | Preview |
INTRODUCTION
Medical devices, including high-risk medical devices, have greatly contributed to recent improvements in the management of diabetes. However, the clinical evidence that is submitted for regulatory approval is not transparent, and thus a comprehensive summary of the evidence for high-risk devices approved for managing diabetes in Europe is lacking. In the framework of the Coordinating Research and Evidence for Medical Devices group, we will, therefore, perform a systematic review and meta-analysis, which will evaluate the efficacy, safety and usability of high-risk medical devices for the management of diabetes.
METHOD AND ANALYSIS
This study has been reported according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. We will search Embase (Elsevier), Medline All (Ovid), Cochrane Library (Wiley), Science Citation Index Expanded and Emerging Sources Citation Index (Web of Science) to identify interventional and observational studies that evaluate the efficacy and/or safety and/or usability of high-risk medical devices for the management of diabetes. No language or publication dates' limits will be applied. Animal studies will be excluded. In accordance with the Medical Device Regulation in European Union, high-risk medical devices are those in classes IIb and III. The following medical devices for diabetes management are considered as having a high risk: implantable continuous glucose monitoring systems, implantable pumps and automated insulin delivery devices. Selection of studies, data extraction and quality of evidence assessment will be performed independently by two researchers. Sensitivity analysis will be performed to identify and explain potential heterogeneity.
ETHICS AND DISSEMINATION
No ethical approval is needed for this systematic review, as it is based in already published data. Our findings will be published in a peer-reviewed journal.
PROSPERO REGISTRATION NUMBER
CRD42022366871.
Actions (login required)
 |
Edit item |